yield intervention that is not routinely discussed by providers. 16, 17 A randomized-controlled trial that evaluated the effects of a brief prenatal behavioral intervention on risk behaviors for maternal CMV found that it was modestly effective in changing behaviors. 18 This trial did not evaluate incidence of primary CMV in the participants.
Regarding treatment of maternal CMV to prevent congenital infection, hyperimmune globulin (HIG) has unclear efficacy. 19, 20 Nigro et al performed a nonrandomized trial on the use of HIG in women who had a primary CMV infection and had a positive amniocentesis for CMV at less than 21 weeks' gestation or declined an amniocentesis. Those who received HIG had a significantly lower rate of congenitally infected neonates (40 vs. 16%, p ¼ 0.02). 19 While promising, this small study was neither randomized nor blinded. Revello et al published a small randomized-controlled trial in which 124 women with primary CMV were randomized to HIG versus placebo. They reported a rate of congenital infection of the fetus (confirmed by amniocentesis) or newborn of 44% in the placebo group versus 30% in the HIG group, but this did not reach statistical significance (p ¼ 0.13). 20 A decision analysis published by Cahill et al in 2009 evaluated the cost-effectiveness of CMV screening and treatment. They found that universal screening for primary maternal CMV is cost-effective when evaluating neonatal quality of life compared with either risk-based screening or screening based on suspicious ultrasound findings. 21 To our knowledge, there have been no studies which have evaluated both behavioral intervention and HIG in combination for prevention and treatment of maternal CMV and no cost analysis has evaluated CMV screening including both maternal and neonatal quality of life. Therefore, our objectives were to use decision analysis to determine the necessary effectiveness of intravenous HIG as well as targeted behavioral counseling for prevention of congenital CMV, and the threshold incidence of primary CMV that would make universal maternal CMV screening in pregnancy cost-effective.
Materials and Methods
We developed a decision model to evaluate the costs and benefits of two strategies for prevention and treatment of congenital CMV, universal maternal serum screening, or routine, risk-based screening, in a theoretical cohort of 4 million women pregnant annually in the United States. In the universal screening group, it was assumed that all pregnant women underwent one-time serum screening for CMV prior to 20 weeks of gestation. All women with serologic evidence of primary CMV were treated with monthly HIG to decrease fetal transmission. We assumed that only some seropositive women would undergo amniocentesis and that amniocentesis would occur after 20 weeks of gestation. All seronegative women received a behavioral intervention to reduce their risk of primary CMV in the second and third trimesters. We did not account for the possibility of reinfection in seropositive women because serology is of unclear utility in such cases; as such, we did not model behavioral intervention in seropositive women. Following initial negative serum screening, serum screening could be resent at the discretion of the provider with suspicious ultrasound abnormalities which included intracranial calcifications, microcephaly, hyperechoic bowel, and fetal growth restriction. We did not model routine repeat screening without ultrasound abnormalities. If primary CMV was detected on serum screening or amniocentesis, women were treated with monthly HIG. In the routine care group, serum CMV screening was performed only with suspicious ultrasound abnormalities. Women who then had a positive serum screen for primary CMV were treated with monthly HIG. In both the universal screening and routine care groups, we accounted for the possibility of second and third trimesters primary CMV infection, modified by the effectiveness of behavioral intervention in the screening group. Additionally, in both groups, women may have elected to terminate a pregnancy following a serum screen, ultrasound abnormalities, or amniocentesis consistent with primary CMV, or following an abnormal ultrasound in general. 19, [22] [23] [24] [25] [26] Women with primary CMV who elected for termination did not receive monthly HIG. Women in both groups (universal screening and routine care) who screened positive for primary CMV underwent monthly ultrasounds until delivery. Neonates were screened for CMV if either maternal serum screening or amniocentesis was positive, or with symptoms concerning for CMV at birth. All neonates with symptomatic CMV were treated with antivirals, and all neonates with long-term disability from CMV received standard pediatric follow-up for CMV. The analysis was performed from a health care perspective to estimate the total expenditures related to CMV screening and treatment.
To obtain base case probability point estimates and confidence intervals, we conducted an English language search of PubMed to identify relevant publications. The Medical Subject Heading (MeSH) search term cytomegalovirus and the MeSH descriptor cost were used initially and then expanded to find the necessary data for the model. The final search terms included: pregnancy, cytomegalovirus, hyperimmune globulin, cytomegalovirus screening, congenital cytomegalovirus, and behavioral intervention. The search was limited to English language articles only but was not limited by publication date or country of origin. All identified documents were examined and those that were relevant were retrieved. Reference lists of retrieved documents were manually reviewed to identify additional publications. Point estimates were determined from published randomized-controlled trials, prospective cohorts, and national vital statistic data when possible. Retrospective cohorts or review studies were used when no other sources of information were available. If there was not one study that was methodologically superior, we calculated base case point estimates as the unweighted mean or median of the available database on their distributions (►Table 1). We made the following assumptions regarding probability point estimates and confidence intervals given limited data: (1) fetal infection always resulted in congenital CMV, but the neonate could be symptomatic or asymptomatic; (2) an adverse reaction to HIG led to 1 hospital day (range, 0-2 days); (3) fetal CMV infection led to a twofold increased risk of an intrauterine fetal demise (IUFD) (range, relative risk [RR] 1.0-2.0); and (4) treatment with HIG had no effect on IUFD or preterm delivery risk (range, RR 0.5-2.0) (►Table 1). 
Efficacy of interventions
Reduction in fetal infection with HIG 0.00 0-1.0 19, 20 Reduction in maternal seroconversion with behavioral intervention 0.85 0-1.0 6, 11, 14, 15 Probability of termination Severe reaction to HIG 0.001 0-0.002 19, 20, 59, 60 Loss after amniocentesis 0.001 0.001-0.005 21, [61] [62] [63] [64] Fetal CMV infection without treatment 0.40 0.10-0.70 43, 65 Symptomatic CMV following fetal infection 0.10 0.05-0.10 43, 44, [66] [67] [68] Severe disability
Asymptomatic CMV at birth 0.14 0-0.15 19, 20, 43, 44, [66] [67] [68] Symptomatic CMV at birth 0.90 0.50-0.90
Preterm delivery 0.03 0.02-0.11
Term delivery 0.02 0.01-0.02 36 Intrauterine fetal demise Baseline 0.006 0.005-0.012 69 Fetal CMV infection 0.012 0.005-0.035 19, 20 Preterm delivery Baseline 0.12 0.10-0.12 37 Fetal CMV infection 0.23 0.10-0.36 20, 68 Neonatal death Preterm delivery 0.01 0.001-0.38 38, 70, 71 Term delivery 0.0007 0.0002-0.001 38, [70] [71] [72] [73] Neonatal CMV infection 0.05 0.01-0.10 2, 19, 43, 67, 68 Abbreviations: CMV, cytomegalovirus; HIG, hyperimmune globulin. a Internal data.
We derived utilities from published literature. Utilities are a means of evaluating the relative quality of life as compared with health. We determined six maternal health states and three neonatal health states that would be relevant for this analysis. The maternal health states included health after the following: pregnancy termination (utility ¼ 0.94, range 0.77-0.99), miscarriage or fetal loss (utility ¼ 0.94, range 0.66-0.99), intrauterine fetal demise (utility ¼ 0.92, range 0.6-0.99), neonatal death (utility ¼ 0.92, range 0.6-0.99), delivery of a severely affected child from CMV or cerebral palsy (utility ¼ 0.5, range 0.01-0.9), and delivery of a healthy child (utility ¼ 1). Maternal utilities were derived using the standard gamble and time tradeoff methods. [27] [28] [29] [30] [31] [32] [33] The neonatal health states included: normal health (utility ¼ 1), severe disability (utility ¼ 0.48, range 0.01-0.89), and death (including termination, miscarriage, IUFD, and neonatal death (utility ¼ 0). 34, 35 The neonatal utilities were derived using the Health Utilities Index and author judgment. 34, 35 Severe disability was defined as serious medical conditions that significantly limit working capacity and include cerebral palsy, mental retardation, blindness, deafness, and epilepsy. 36 We assumed that the average maternal age at delivery was 26 years (the mean age of first birth in the United States) and the average maternal life expectancy was 81 years. 37, 38 A termination or miscarriage was assumed to reduce maternal quality of life for 1 year, an IUFD or neonatal death was assumed to reduce maternal quality of life for 2 years, and a severely affected child was assumed to impact maternal quality of life for the lifespan of the child. For each of these health states, a maternal utility of 0.99 was assigned for the remainder of her life expectancy following the time frame mentioned for each state. We assigned an average life expectancy of 79 years for healthy infants (lower than the average maternal life expectancy because it includes 50% males, who have a shorter life expectancy), 65 years for infants with cerebral palsy, and 20 years for infants with severe manifestations of CMV. 34, 35 To calculate qualityadjusted life years (QALYs), we assumed a discounting rate of 3% in the base case (range 0-5%) (►Table 2). To determine the exact QALY value, the utility value associated with a given state of health was multiplied by the years lived in that state. Discounting assumes that current health is worth more than future health meaning that the utility of each subsequent year is decreased by 3% in the above QALY calculation.
We derived cost estimates in a similar fashion to the probability estimates, but additionally queried local and national hospital and insurance data (►Table 2). We adjusted all costs to reflect 2018 U.S. dollars. The costs accounted for in the model included the cost of maternal CMV testing, maternal follow-up and treatment, maternal delivery, neonatal screening in those whose mothers were CMV screen positive and in those who were symptomatic at birth, neonatal care, which included the cost of antiviral treatment, and the cost of longterm disability. Delivery costs were based on the gestational age at delivery. Long-term care costs included only direct medical expenses, thus productivity losses were not included.
The primary outcome was the cost per maternal QALY gained with a willingness to pay of $100,000 per QALY gained. [39] [40] [41] Neonatal QALYs can only be meaningfully calculated when termination does not occur because a termination for any reason leads to a neonatal QALY of 0. Therefore, we also evaluated the cost per neonatal QALY gained, assuming termination was not performed, again using a willingness to pay of $100,000 per QALY. In addition to the base case analysis, we performed one-, two-, and three-way sensitivity analyses. In particular, this allowed for an investigation into how the incidence of primary maternal CMV, the effectiveness of a behavioral intervention, and effectiveness of HIG might interact. Finally, Monte Carlo simulation (a computational algorithm that relies on repeated random sampling of all variables across their confidence intervals based on their distributions) was utilized given the uncertainty of many of the point estimates. In the Monte Carlo simulation, β distributions were used for probability and utility estimates, log normal distributions were used for RRs, and gamma distributions were used for cost variables. Given the plausible variation in all of the probabilities and cost estimates included in the model, no variable was excluded from the Monte Carlo analysis. One hundred thousand simulations were run to estimate the percentage of time that universal CMV screening would be cost-effective as compared with routine care.
We performed all analyses using TreeAge Pro 2018 Suite (TreeAge Software, Inc., Williamstown, MA). The study did not involve human subjects and was exempted from Institutional Review Board approval.
Results
In the base case we assume that HIG is ineffective, primary maternal CMV incidence is 1% of those previously seronegative (0.45% of all pregnancies assuming a CMV seroprevalence of 55.5%), and behavioral intervention effectiveness is 85%. Under these assumptions, universal screening is costeffective, costing $84,773 per maternal QALY gained. In oneway sensitivity analyses, for universal screening to remain cost-effective, primary CMV incidence needs to be more than 0.89% and behavioral intervention needs to be more than 75% effective. If HIG is 30% effective, universal screening costs $74,833 per maternal QALY gained, and incidence of primary CMV must be more than 0.82%.
Using two-and three-way sensitivity analyses, if primary CMV incidence, HIG effectiveness, or behavioral intervention effectiveness individually decreases, the other variables must increase for universal screening to remain cost-effective. Similarly, if primary CMV incidence, HIG effectiveness, or behavioral intervention effectiveness individually increases, the other variables can decrease and universal screening will remain cost-effective (►Fig. 1). For example, at a primary CMV incidence of less than 0.64%, universal screening is not cost-effective at any efficacy of HIG or behavioral intervention. At CMV incidence of 0.8% and HIG effectiveness of 30%, behavioral intervention would have to be 93% effective for universal screening to remain costeffective. However, at CMV incidence of 2 and 4% and HIG effectiveness of 30%, behavioral intervention only needs to be 30 and 11% effective, respectively. [27] [28] [29] [30] 33, 35 Care of neonate with severe disability from cerebral palsy 13.39 0.19-49.50 [27] [28] [29] [30] 33, 35 Care of healthy child 26.77 18.63-55 27, 28 Abbreviations: CMV, cytomegalovirus; HIG, hyperimmune globulin; PCR, polymerase chain reaction; QALY, quality adjusted life year; USD, U.S. Dollar. a Internal data.
Using Monte Carlo simulation, universal screening is costsaving in 21.1% of simulations and is cost-effective at a threshold of $100,000 per maternal QALY in an additional 31.3% (►Fig. 2). Overall, universal screening is cost-effective or cost-saving in 52.4% of all possible scenarios.
In the setting in which a woman does not consider termination under any circumstance and HIG is ineffective, universal screening is cost-effective ($30,222/neonatal QALY gained). In sensitivity analyses, this model is most sensitive to the rate of primary maternal CMV infection and the decrease in seroconversion following behavioral intervention. In fact, universal screening remains cost-effective if the incidence of primary maternal CMV is 0.4% or if behavioral intervention reduces the rate of seroconversion by at least 33%. Additionally, a greater reduction in seroconversion during pregnancy with behavioral intervention allows universal screening to remain cost-effective at lower rates of primary maternal CMV and HIG effectiveness (►Figs. 3 and 4). Using Monte Carlo simulation, universal screening is cost-saving in 19.7% of simulations and is cost-effective at a threshold of $100,000 per neonatal QALY in an additional 43.1% (►Fig. 5). Overall, universal screening is cost-effective or cost-saving in 62.8% of all possible scenarios.
Comment
In the United States, universal maternal screening for CMV is cost-effective from the maternal standpoint even assuming HIG is ineffective, but only assuming the incidence of primary CMV is more than 0.89% of those previously seronegative (therefore, 0.4% of women assuming a CMV seroprevalence of 55.5%). Behavioral counseling to prevent seroconversion during pregnancy and HIG to prevent and treat congenital CMV, if they are efficacious, allows universal screening to be cost-effective at lower rates of primary CMV infection. From a neonatal perspective, in a cohort in which no woman terminates her pregnancy, universal screening is cost-effective at lower rates of primary CMV.
In this analysis, our base case assumed that HIG was ineffective because the efficacy is unproven at this time and is only recommended within a research study. We did not account for the risk of reinfection in seropositive women because serology may not be useful for diagnosis and none of the current studies has evaluated the efficacy of HIG in the setting of reinfection. We similarly did not model a behavioral intervention for those women who were CMV screen positive. Additionally, given the lack of data, HIG was assumed to have no effect on IUFD or preterm delivery risk. The study by Revello et al noted a higher absolute risk of prematurity in the HIG arm; however, the finding was not statistically significant and the numbers were small. 20 Alternatively, it is possible that if HIG proves effective in reducing the risk of fetal transmission and congenital infection, prematurity may be decreased. To account for these possibilities, we varied this parameter in our sensitivity analyses. Studies evaluating the effectiveness of a behavioral intervention are difficult to conduct and many that have been performed have significant design flaws. 6, 11, 14, 15 To account for this, we evaluated all possibilities for behavioral intervention effectiveness (0-100%). Regarding neonatal care, we did not model universal neonatal CMV screening because while it may be cost-effective, 42 it is not currently standard of care. Finally, we only modeled treatment for long-term severe disability from CMV and as such, we did not model the follow-up and treatment for mild to moderate hearing loss caused by congenital CMV.
Strengths of this study are the ability to evaluate large ranges of costs and probabilities. In the setting of limited primary data and uncertainty about the efficacy of the available interventions, including HIG and behavioral intervention, this allows for a critical evaluation of thresholds necessary to make these interventions cost-effective. We created a model that, we believe, will accurately reflect clinical practice, should HIG prove to be efficacious. This includes a behavioral intervention for those women found to be seronegative and multiple doses of HIG in those found to be seropositive. This is in contrast to the prior cost-effectiveness analysis performed by Cahill et al 21 which did not consider the impact of a behavioral intervention and also did not take into account multiple doses of HIG. While the data on behavioral intervention for primary maternal CMV prevention is sparse, hygiene education could be easily implemented as part of prenatal care, therefore making it necessary to include in this model. Finally, our outcomes evaluate both maternal and neonatal quality of life.
The major limitation of all cost analyses is that the evaluation is only as good as the available data. The incidence of seroconversion varies widely based on setting-country, urban versus rural, and high versus low income. 4 We have used conservative estimates based on data from high socioeconomic countries which should reflect the population of the United States. Most importantly, regarding treatment of maternal CMV with HIG to prevent congenital infection, there is unclear evidence of efficacy. 19, 20 Subsequent randomized-controlled trials are ongoing including a randomized-controlled trial evaluating HIG in the treatment of primary maternal CMV (Clinical-Trials.gov, ID number: NCT01376778). This current analysis may help guide policy in the future once this trial is completed and with more accurate data from this trial, our analysis could be reperformed. Another limitation is that outcomes such as a termination or miscarriage lead to a neonatal QALYof 0. Because of the nature of this specific analysis, we primarily ran the analyses from the maternal point of view, but secondarily ran the analyses from a neonatal standpoint excluding terminations, allowing it to be more generalizable. Finally, we did not account for indirect costs, such as loss of work.
The birth prevalence of congenital CMV in the United States has been reported to be 0.7%, 43, 44 with up to 75% of these as a result of maternal reinfection. 45 Assuming a fetal transmission rate of 40% following a primary infection (and much lower, around 1.5%, in the setting of reinfection 43 ), the overall rate of primary CMV may be closer to 0.7% in many populations.
Based on the results of this analysis, if the results of the ongoing studies of treatment efficacy of HIG for primary maternal CMV demonstrate an efficacy of 30% along with an incidence of primary CMV of more than 0.82%, universal screening may be cost-effective. Even if the ongoing studies do not demonstrate HIG efficacy, universal CMV screening is still cost-effective as long as the incidence of CMV remains above 0.89%. If primary prevention of CMV using behavioral intervention is more effective than expected, universal screening will remain cost-effective at a lower CMV incidence.
Note
This study was presented as a poster at the 2015 Society for Maternal-Fetal Medicine Annual Meeting, February 2-7, 2015, San Diego, CA.
